Make a plan before your last dose Rutledge recommends using your time on a GLP-1 medication intentionally: Develop non-food ways to cope with stress, focus on improving the quality of your diet rather than simply eating less and expect hunger to return not as a sign you've failed, but as a normal biological response
Pool of Seven Controlled Clinical Trials Adverse reactions were also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in seven controlled clinical trials which included two placebo-controlled trials (SURPASS-1 and -5), three trials of MOUNJARO in combination with metformin, sulfonylureas, and/or SGLT2 Inhibitors (SURPASS-2, -3, -4) [see Clinical Studies (14.3)] and two additional trials conducted in Japan
If vomiting persists beyond 6 months or is accompanied by early satiety and postprandial bloating, a four-hour scintigraphic gastric emptying study can determine whether semaglutide has produced clinically significant gastroparesis
Paul Wright, consultant cardiovascular pharmacist at Barts NHS Trust, commented: This is great news we saw a 20% risk reduction in major adverse coronary events in the SELECT trial, so [I am] keen to see how this can be offered to patients in practice